recipient of the Audacious Project

Charting a new era of antibiotics

Phare Bio is a social venture using novel AI and Deep Learning to tackle the world’s most urgent threats.
Contact Us

Partnered with the Collins Lab at MIT and the Broad Institute on its AI/deep learning platform for antibiotic discovery work.

Phare Bio is the recipient of the Audacious Project, a collaborative funding initiative between TED and other nonprofits to unlock social impact on a grand scale.

Imagine a world in which common diseases become untreatable.
That world may soon be a reality.

The aggressive evolution of antibiotic-resistant bacteria and a dwindling antibiotic discovery pipeline have resulted in an antimicrobial resistance (AMR) crisis. 

Covid-19 has only highlighted the urgency with approximately 15% of hospitalized patients suffering from bacterial co-infections. There is a critical need for new antibiotics — and yet pharmaceutical and biotechnology companies have largely abandoned the space for more lucrative markets.
Every 11 seconds someone in the U.S. acquires a resistant infection; every 15 minutes someone dies as a result of one.
* according to the Centers for Disease Control and Prevention

A Unique Business Model

Insufficient market incentives and rapid antibiotic resistance leave us vulnerable to the most deadly bacteria. Yet in the midst of this antibiotic crisis, another door is opening. Phare Bio launched in 2020 with an ambitious social venture model and the latest advances in machine learning to address this critical need. Phare addresses the  “valley of death” -- the stage in preclinical development when most drugs fail -- with donor funding, and takes on more costly clinical development with strategic commercial partnerships and company spin-outs. This model enables Phare to develop a novel pipeline of AI-optimized antibiotic candidates, derisk these candidates through preclinical development, and build a sustainable clinical path to ensure that these therapies reach the patients in greatest need. 

Philanthropic funding

Learning Platform

We screen 1000x as many molecules, 5x faster, at 100x greater success rate for the negligible cost of computing to predict and design novel antibiotics.


With our AI-optimized candidates, we conduct drug metabolism, toxicology pharmacokinetics and efficacy assays to declare lead candidates.

Preclinical development

Our lead candidates move into preclinical development, where we test drug delivery, and conduct extensive in vivo efficacy profiling.
Commercial funding

Clinical Development

Once our candidates are derisked, we partner with large pharma companies or spin out new companies for clinical trials, leveraging Phare’s initial donor funding for long-term sustainability.

Phare streamlines and optimizes the development process by integrating world-class expertise and decades of experience in artificial intelligence (AI), bioengineering, and pharmaceutical development to rapidly discover and develop novel classes of antibiotics that target urgent threats like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. This unique and self-sustaining approach will enable us to outpace the emergence and global dissemination of antibiotic resistance.

Meet our team

Akhila Kosaraju

M.D., CEO & President
Dr. Kosaraju has spent her career building companies and driving innovation in infectious disease and computational biology...

James J. Collins

Ph.D., Co-founder & Chair of the Scientific Advisory Board
Dr. Collins is the Termeer Professor of Medical Engineering and Science, a Professor of Biological Engineering...

Jonathan M. Stokes

Ph.D., Co-Founder & Scientific Director
Dr. Stokes is an Assistant Professor in the Department of Biochemistry and Biomedical Sciences at McMaster...

Scientific Advisory Board

James J. Collins (Chair)
Termeer Professor of Medical Engineering and Science, a Professor of Biological Engineering at MIT and a member of the Harvard-MIT Health Sciences and Technology faculty 
Regina Barzilay
Delta Electronics Professor in MIT’s Department of Electrical Engineering and Computer Science and a faculty lead for the MIT Abdul Latif Jameel Clinic for Machine Learning in Health (J-Clinic)
Tommi S. Jaakkola
Thomas Siebel Professor of Electrical Engineering and Computer Science at the Institute for Data, Systems, and Society at MIT
Sarah Fortune
John LaPorte Given Professor of Immunology and Infectious Diseases at the Harvard TH Chan School of Public Health and Chair of the Department of Immunology and Infectious Diseases
César de la Fuente
Presidential Assistant Professor, Departments of Psychiatry and Microbiology, Perelman School of Medicine at the University of Pennsylvania
Deborah T. Hung
Associate professor in the Department of Molecular Biology at Massachusetts General Hospital and in the Department of Microbiology and Immunobiology at Harvard Medical School, and the director of the Infectious Disease Program at the Broad Institute of MIT and Harvard
Jonathan M. Stokes
Assistant Professor, Department of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute for Infectious Disease Research, David Braley Centre for Antibiotic Discovery, McMaster University
Gerry Wright
Director- Institute for Infectious Disease Research and Professor - Department of Biochemistry and Biomedical Sciences at McMaster University
Eric Brown
Distinguished Professor at McMaster University in the Department of Biochemistry and Biomedical Sciences and member of the M.G. DeGroote Institute for Infectious Disease Research at McMaster University
Nathalie Q. Balaban
Professor of Biological Physics and heads the Laboratory of Self Replicating Matter in the Physics Department at the Hebrew University of Jerusalem
Jens Nielsen
CEO of BioInnovation Institute, Copenhagen, Denmark and Professor of Systems Biology at Chalmers University of Technology, Gothenburg, Sweden
Laura Piddock
Professor of Microbiology at the University of Birmingham, United Kingdom, and Director of Scientific Affairs, Global Antibiotic Research and Development Partnership (GARDP)

Let’s tackle this together.

If you´re interested in partnering, joining our team or learning more, send us a message.
Contact Us